Aethlon Medical Completes Acquisition of Cell Activation.

Business Editors/Health & Medical Writers

BIOWIRE2K

SAN DIEGO--(BW HealthWire)--April 6, 2000

Aethlon Medical Inc., (OTCBB:AEMD) announced today that it has completed the acquisition of Cell Activation Inc. of San Diego.

Cell Activation is the developer of novel tests that identify inappropriate and damaging cell activation associated with trauma, cardiovascular surgery, and autoimmune diseases. Cell Activation has also developed tests that identify damaging enzyme activity in blood and blood products. Therapies designed to treat cell activation and damaging enzymes are being developed as new Hemopurifier(TM) applications. The Hemopurifier(TM) is a proprietary Aethlon Medical technology designed to remove target intoxicants from the body.

Regarding the acquisition of Cell Activation, Franklyn S. Barry, president & chief executive officer of Aethlon Medical stated, "We are delighted to join with the extraordinary scientists and business people who have developed the Cell Activation technology to this point. We believe that this new relationship puts Aethlon Medical on the cutting edge of the growing field of complement activation diagnosis and therapy, and adds a major new application for our Hemopurifier(TM) extracorporeal treatment technology."

About Aethlon Medical

Aethlon Medical is a leading developer of extracorporeal treatment technologies. Utilizing a proprietary platform technology known as the Hemopurifier(TM), Aethlon Medical is able to remove targeted intoxicants from the blood without the side effects normally associated with other methods of treatment. The first family of Hemopurifiers to be commercialized have been developed for the purpose of removing harmful metal intoxicants, including iron, lead, and cisplatin. Other products now in development include Hemopurifiers that treat plutonium intoxication, drug overdoses, and Hemopurifiers designed to reduce the body burden of viruses such as HIV and Hepatitis C.

For more information on recent developments at the company, visit the Aethlon Medical Web site at http://www.aethlonmedical.com.

For additional information, contact: James A. Joyce, chairman by email: [e-mail] or by phone at 858/456-5777.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical Inc. (the "company"), or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Readers of this press release may obtain additional information on the company in reports and other information filed in accordance with the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Such reports and other information filed by the company can be inspected and copied at the public reference facilities maintained by the Commission at the Public Reference Room, 450 Fifth Street, N.W., Washington, DC 20549. Copies of such material can also be obtained at prescribed rates from the Public Reference Section of the Commission, Washington, DC 20549 or by calling the Commission at 800/SEC-0330. In addition, Registration Statements and other filings made with the Commission through its Electronic Data Gathering Analysis and Retrieval System ("EDGAR") and publicly available through the Commission's Web site located at http://www.sec.gov.